Company Encyclopedia
View More
name
Biora Therapeutics
BIOR.US
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc.
1.935 T
BIOR.USMarket value -Rank by Market Cap -/-

Financial Score

27/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking187/401
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE31.56%A
    • Profit Margin-3535.76%E
    • Gross Margin100.00%A
  • Growth ScoreA
    • Revenue YoY4855.56%A
    • Net Profit YoY74.24%A
    • Total Assets YoY-58.20%E
    • Net Assets YoY10.23%B
  • Cash ScoreB
    • Cash Flow Margin-2.83%D
    • OCF YoY4855.56%A
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreE
    • Gearing Ratio835.12%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Biora Therapeutics completes restructuring process, now privately held; aims to speed up BioJet™ platform development.

    After completing restructuring, Biora has transitioned into a privately held firm, equipped with long-term funding aimed at expediting the advancement of the BioJet™ platform.

    Unusual Whales·
    US
    BIORQ
    0.00%
    US
    BIOR
    0.00%
    Unusual Whales·
    US
    BIORQ
    0.00%
    US
    BIOR
    0.00%

    Biora Therapeutics completes successful restructuring process to emerge as privately held company, focusing on BioJet™ platform.

    After completing its restructuring, Biora now operates as a privately held company. The company has secured long-term financing to expedite the advancement of its BioJet™ platform. This move comes as Biora aims to enhance its development and growth strategies, ensuring future progress.

    Unusual Whales·
    US
    BIOR
    0.00%
    Unusual Whales·
    US
    BIOR
    0.00%

    Biora Therapeutics finishes restructuring, now privately held with funds to boost BioJet™ platform development.

    After completing a restructuring process, Biora has transitioned into a privately owned company. The company has secured long-term funding that will be utilized to expedite the advancement of the BioJet™ platform. This move signals a significant milestone for Biora as they focus on enhancing their technology. The specific amount of financing and other details surrounding the transition were not disclosed publicly.

    Unusual Whales·
    US
    BIOR
    0.00%
    US
    BIORQ
    0.00%
    Unusual Whales·
    US
    BIOR
    0.00%
    US
    BIORQ
    0.00%

    Biora completes restructuring to become privately held, secures financing to advance BioJet™ platform development.

    After completing the restructuring process, Biora reemerges as a privately owned company. They have secured long-term financing to expedite the advancement of their BioJet™ platform.

    Unusual Whales·
    US
    BIOR
    0.00%
    Unusual Whales·
    US
    BIOR
    0.00%

    Biora Therapeutics restructures, now privately held with financing to accelerate BioJet™ platform development.

    After completing a successful restructuring phase, Biora has transitioned into a privately owned entity. The company has secured substantial long-term funding to expedite the progression of its innovative BioJet™ platform. This strategic move is aimed at ensuring rapid advancements in the company's research and development initiatives.

    Unusual Whales·
    US
    BIOR
    0.00%
    Unusual Whales·
    US
    BIOR
    0.00%
    © 2025 Longbridge｜Disclaimer